FDA Inspection 1284298 — Roswell Park Cancer Institute Corporation. Div. of Pathology

Roswell Park Cancer Institute Corporation. Div. of Pathology — FEI 1372120

The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. of Pathology on September 19, 2025 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 19, 2025
Fiscal Year
2025
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Buffalo, NY (United States)